Acer Therapeutics "announced that it has entered into a definitive agreement for the purchase and sale of 2,920,306 shares of the Company’s common stock at a purchase price of $0.916 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue warrants to purchase up to 2,920,306 shares of common stock. The warrants will have an exercise price of $0.791 per share, will be exercisable immediately following issuance and have a term of five and one-half years from the issuance date. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACER:
- Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes
- Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Biotech Alert: Searches spiking for these stocks today
- Acer Therapeutics Plummets on Pausing ACER-801 Trial
- Acer reports Phase 2 trial of ACER-801 did not achieve statistical significance